New Anticoagulants for the Prevention of Deep Venous Thrombosis Stavros ApostolakisEduard ShantsilaGregory Y. H. Lip Commentary 17 September 2012 Pages: 793 - 795
Economic Evaluation and Cost-Effectiveness Thresholds John A. VernonRobert GoldbergJoseph Golec Current Opinion 17 September 2012 Pages: 797 - 806
A Cost-Effectiveness Model Comparing Rivaroxaban and Dabigatran Etexilate with Enoxaparin Sodium as Thromboprophylaxis after Total Hip and Total Knee Replacement in the Irish Healthcare Setting Laura McCullaghLesley TilsonMichael Barry Original Research Article 17 September 2012 Pages: 829 - 846
An Economic Evaluation of Docetaxel and Paclitaxel Regimens in Metastatic Breast Cancer in the UK Ágnes BenedictDavid A. CameronStephen E. Jones Original Research Article 17 September 2012 Pages: 847 - 859
30 Years of Pharmaceutical Cost-Utility Analyses Peter J. NeumannChi-Hui FangJoshua T. Cohen Original Research Article 17 September 2012 Pages: 861 - 872
Cost-Effectiveness Analysis of Adjuvant Therapy for Operable Breast Cancer from a Chinese Perspective Peng LiubaoWan XiaominCao Junhua Original Research Article 17 September 2012 Pages: 873 - 886